PLD + Bevacizumab (platinum-resistant recurrent ovarian, AURELIA)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN` `DRUG-BEVACIZUMAB`

ID	`REG-PLD-BEV-OVARIAN`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-AURELIA-PUJADE-LAURAINE-2014` `SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025`

Notes

AURELIA PLD arm: PFS 5.4 vs 3.5 mo (HR 0.57 vs PLD alone); ORR 17.4% vs 7.8%. Combined-cohort AURELIA mPFS 6.7 vs 3.4 mo overall (HR 0.48). Preferred platinum-resistant chemo+bev backbone in patients with prior taxane-induced peripheral neuropathy (avoids re-exposure). Cap cumulative anthracycline at lifetime ~550 mg/m².

Used By

Indication

IND-OVARIAN-2L-PLAT-RES-MIRVETUXIMAB - IND-OVARIAN-2L-PLAT-RES-MIRVETUXIMAB
IND-OVARIAN-2L-PLAT-RES-PLD-BEV - IND-OVARIAN-2L-PLAT-RES-PLD-BEV